Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
tk4RSQsJ6ccyGYy0
Listen
